Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC.

Background: Sotorasib 960 mg once daily is approved to treat KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). Sotorasib exhibits non-dose proportional pharmacokinetics and clinical responses at lower doses; therefore, we evaluated the efficacy and safety of sotorasib 960 mg and 240 mg.

Methods: In this phase 2, randomized, open-label study, adults with KRAS G12C-mutated advanced NSCLC received sotorasib 960 mg or 240 mg once daily.

Targeted therapeutic options in early and metastatic NSCLC-overview.

The complex therapeutic strategy of non-small cell lung cancer (NSCLC) has changed significantly in recent years. Disease-free survival increased significantly with immunotherapy and chemotherapy registered in perioperative treatments, as well as adjuvant registered immunotherapy and targeted therapy (osimertinib) in case of EGFR mutation. In oncogenic-addictive metastatic NSCLC, primarily in adenocarcinoma, the range of targeted therapies is expanding, with which the expected overall survival increases significantly, measured in years.

[Endobronchial ultrasonography in postintubation tracheal stenosis].

Introduction: The correct evaluation of the tracheal wall's structure is necessary for the management of postintubation tracheal stenosis (PTS). Endobronchial ultrasonography (EBUS) is suitable for visualisation of layers of the tracheal wall and the assessment of cartilages' damage.

Aim: The authors assessed the usefulness of EBUS in the anatomical characterization of PTS and in the decision making in its therapy.

[Our experience using autofluorescence bronchoscopy].

Introduction: Lung cancer is responsible for most cancer deaths in the world. The main reason for the poor prognosis is late diagnosis. Many patients could be successfully treated in early stage.

[Endobronchial ultrasonography].

Endobronchial ultrasonography is an imaging method which has been developed during the last decade. It can be performed by applying tools that are used today during conventional bronchofiberscopy. This method is recommended for identifying processes that affect the bronchial wall and the mediastinal lesions next to central airways as well as for localizing peripheral lung lesions.

[Tumor-like tracheal and lung diseases in biopsy samples].

Tumor like miscellaneous lung diseases are rare conditions. They can be confused with benign and malignant tumors. We describe the clinicopathological features some of this conditions i.

[Benign pulmonary and tracheal tumors in our biopsies].

Introduction: Benign lung and trachea tumors account for only a small percentage of a bronchologist's and a histopathologist's everyday practice.

Aims: The authors describe the clinicopathological features some of these tumors because they may be confused with malignant conditions. To avoid misdiagnosis of malignancy the knowledge of bronchologic and histologic appearance of these tumors is important.